Company / Debt per Share
Theravance Biopharma, Inc. Debt per Share History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
-
FY2023
5-year range
$0.00 / $9.58
FY2019-FY2023
Trend
-
vs FY2022
Sector context
#80 of 82
Health Care
What the data says
Improved from $10.86 to $0.00 over the past 3 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 82
▼
Key checks
Key Insights
- Peak debt per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.00 | - |
| FY2022 | - | - |
| FY2021 | $9.58 | -11.8% |
| FY2020 | $10.86 | +32.9% |
| FY2019 | $8.17 | -2.2% |
| FY2018 | $8.35 | +97.3% |
| FY2017 | $4.23 | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026